Editorial: Combination therapies for Type 1 diabetes: Why not now?

Immunotherapy

Volumn 2, Issue 3, 2010, Pages 289-291

  Von Herrath, Matthias ^a  

^a LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CD20 ANTIBODY; CD3 ANTIBODY; CYCLOSPORIN; DNA VACCINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOMODULATING AGENT; INSULIN; LEPTIN; RITUXIMAB; THYMOCYTE ANTIBODY; ANTIDIABETIC AGENT; IMMUNOLOGIC FACTOR; PEPTIDE; VENOM;

COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; ACTIVE IMMUNIZATION; ANIMAL; DISEASE MODEL; DRUG COMBINATION; DRUG THERAPY; IMMUNOLOGY; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

ANIMALS; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; DRUG THERAPY; DRUG THERAPY, COMBINATION; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY, ACTIVE; PEPTIDES; VENOMS;

EID: 77953392562     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.23     Document Type: Editorial

References (18)

1. Couri CE, Oliveira MC, Stracieri AB et al.: C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA 301, 1573-1579 (2009).
2. Voltarelli JC, Couri CE, Stracieri AB et al.: Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed Type 1 diabetes mellitus. JAMA 297, 1568-1576 (2007).
3. Huurman VA, Hilbrands R, Pinkse GG et al.: Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation. PLoS One 3, E2435 (2008).
4. Sutherland DE, Sibley R, Xu XZ et al.: Twin-to-twin pancreas transplantation: reversal and reenactment of the pathogenesis of Type I diabetes. Trans. Assoc. Am. Physicians 97, 80-87 (1984).
5. Cure P, Pileggi A, Froud T et al.: Alterations of the female reproductive system in recipients of islet grafts. Transplantation 78, 1576-1581 (2004).
6. Bresson D, Togher L, Rodrigo E et al.: Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest. 116, 1371-1381 (2006).
7. Chatenoud L, Thervet E, Primo J, Bach JF: Anti- CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc. Natl Acad. Sci. USA 91, 123-127 (1994).
8. Alleva DG, Maki RA, Putnam AL et al.: Immunomodulation in Type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope. Scand. J. Immunol. 63, 59-69 (2006).
9. Herold KC, Gitelman SE, Masharani U et al.: A single course of anti-CD3 monoclonal antibody hOKT3g1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of Type 1 diabetes. Diabetes 54, 1763-1769 (2005).
10. Herold KC, Hagopian W, Auger JA et al.: Anti-CD3 monoclonal antibody in new-onset Type 1 diabetes mellitus. N. Engl. J. Med. 346, 1692-1698 (2002).
11. Keymeulen B, Vandemeulebroucke E, Ziegler AG et al.: Insulin needs after CD3-antibody therapy in new-onset Type 1 diabetes. N. Engl. J. Med. 352, 2598-2608 (2005). (Pubitemid 41007846)
12. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al.: Rituximab, B-lymphocyte depletion, and preservation of b-cell function. N. Engl. J. Med. 361, 2143-2152 (2009).
13. Ludvigsson J, Faresjo M, Hjorth M et al.: GAD treatment and insulin secretion in recent-onset Type 1 diabetes. N. Engl. J. Med. 359, 1909-1920 (2008).
14. Thrower SL, James L, Hall W et al.: Proinsulin peptide immunotherapy in Type 1 diabetes: report of a first-in-man Phase I safety study. Clin. Exp. Immunol. 155, 156-165 (2009).
15. Bresson D, Fradkin M, Manenkova Y, Rottembourg D, von Herrath M: Genetic-induced variations in the GAD65 T-cell repertoire governs efficacy of anti-CD3/GAD65 combination therapy in new-onset Type 1 diabetes. Mol. Ther. 18, 307-316 (2010).
16. Sherry NA, Chen W, Kushner JA et al.: Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of b-cells. Endocrinology 148, 5136-5144 (2007).
17. Palmer AJ, Valentine WJ, Ray JA et al.: An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with Type 1 diabetes in the UK. Curr. Med. Res. Opin. 23, 895-901 (2007).
18. Filippi CM, von Herrath MG: 99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: viruses, autoimmunity and immunoregulation. Clin. Exper. Immunol. 160(1), 113-119 (2010).